EX-10.1

EX-10.1 2 kymr-ex10_1.htm EX-10.1 EX-10.1

展品10.1

由於這些信息既不重要，也屬於註冊機構視爲私人或機密的類型，因此本展品中已排除了某些確定的信息。被省略的信息在本文件中被標有使用「 [***]」標記的佔位符。

Kymera Therapeutics, Inc。

馬薩諸塞州沃特敦市諾思比肯街500號，4樓，郵編02472

Attn:首席執行官

抄送一份副本（不構成通知）至：Goodwin Procter LLP

收件人：Sarah Solomon 100號北方大道

波士頓，馬薩諸塞州02210 通過電子郵件和聯邦快遞

2024年7月31日

關於修訂和重新訂立的合作和許可協議，日期爲2022年11月15日 [***]

尊敬的女士，先生們：

特此參考賽諾菲安萬特合作及許可協議修訂版本，該協議自2022年11月15日起生效，由德拉華州法律下成立的Kymera Therapeutics，Inc.公司（以下簡稱“Kymera”），以及馬薩諸塞州法律下成立的Genzyme Corporation公司（以下簡稱“ ”），由Kymera與賽諾菲（以下簡稱“協議”）於2023年11月14日簽署的特定函件修訂。Kymera和賽諾菲在本函件中分別稱爲“方方當事人。未在本協議中定義但使用大寫的術語將按照協議中所指定的含義解釋。

雙方希望就[***]展開合作，並根據協議第18.5節的規定，雙方希望根據本文所述的條款和條件修改協議。

鑑於前述條件和本協議中包含的相互約定，各方特此一致同意：

1.1

物料轉移協議的第2.9.1節、第2.9.2節和第2.9.3節在此全文修改並重新規定如下：

2.9

物料轉移.

2.9.1

爲了促進各研究計劃下以及[***]下的活動進行：(a) 賽諾菲安萬特可選擇向凱莫科技提供材料，以便促進凱莫科技在研究計劃或[***]下的研究活動(屆時材料的轉讓應在研究計劃或[***]中指明，或在JRDC的會議記錄中指明)，以及(b) 凱莫科技應向賽諾菲安萬特提供合理數量的材料，以便賽諾菲安萬特進行[***]。

2.9.2

所有板塊根據此轉移的材料第2.9節 (a)將始終是唯一的

ACTIVE/131770235.4

提供方的財產（應理解爲共同擁有的物料將保持共同所有權，儘管在各方之間可能進行物理轉移），只能在接收方根據本協議履行義務或行使權利的情況下使用，僅由接收方控制，不得由接收方交付或爲任何第三方（其他允許的分包商或再許可方除外）而使用或交付，未經提供方事先書面同意，並且不得用於涉及人類對象的研究或測試，除非經書面同意。接收方將根據適用法律和本協議的條款和條件使用這些物料，不得對此類物料進行逆向工程或化學分析，除非研究計劃或[***]中另有規定。

2.9.3

任何一方或代表任何一方所生成的與根據本協議轉讓的材料使用相關的知識產權將受如下規定：第2.9節將受以下規定管轄：

(a)

在授予的許可證下第10條，供應方將獨家擁有所有從使用任何轉移材料生成的數據、信息、結果和報告的權利、所有權和利益，這些轉移材料構成合作化合物、合作候選化合物或已許可產品，僅限於任何在MTA研究中許可且根據 [***] 進行的研究第2.8節（包括 [***]）或根據 [***] 所允許並進行的研究第2.4.8節，具體情況下，這些數據、信息、結果和報告將通過JRDC與供應方共享

(b)

除非根據[公司披露記錄]中的規定，在估值日之後，涉及業務在所有重要方面均按照過去的慣例，在正常情況下進行。第2.9.3(a)節，任何一方或代表任何一方在本協議項下使用合作化合物、合作候選物或許可產品所創造、構想或生成的所有知識產權，將受本協議的規定約束，與MTA研究研究或 [***]相關，將受本協議的規定約束，包括第10條和頁面。第12條。.

1.2

[***]協議現在新增了新的第2.4.8節，內容如下：

2.4.8

[***]在第一個附加降解研究期間，各方將進行 [***]，並根據本協議的條款和雙方達成的書面計劃進行（該計劃稱爲“[***]”）。當前的複製品 [***] 見附件1。爲避免疑義，[***]將由各方與研究計劃下的研究活動分開進行。

(a)

[***] 修訂JRDC將討論、提出和批准對[***]的更新和修正；但是，如果年度授予的公平價值超過40萬美元，則年度授予的股份數量將自動減少，使年度授予的公平價值在40萬美元以下，並且公平價值按公司的財務報表一致確定。年度授權將在授權日期起1年內全部歸屬於基礎股票，或在授權日期後的我們股東年會之前（以先到者爲準），但需持續服務到適用歸屬日期。根據第2.4.8(d)條款，在未經JRDC批准前，對[***]的任何修正均不會生效。

(b)

[***] 勤奮。對於 [***]在此，各方將採取商業上合理的努力來[***]。

(c)

[***].

(d)

運營自主權。根據本協議的條款和條件，包括第9.9節，被分配進行[***]活動的一方將有權就該活動從運營角度做出決策；但是，如果年度授予的公平價值超過40萬美元，則年度授予的股份數量將自動減少，使年度授予的公平價值在40萬美元以下，並且公平價值按公司的財務報表一致確定。年度授權將在授權日期起1年內全部歸屬於基礎股票，或在授權日期後的我們股東年會之前（以先到者爲準），但需持續服務到適用歸屬日期。確保這些決定與本協議和[***]一致；和在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 此外，儘管本協議中的任何內容，賽諾菲安萬特將就[***]擁有最終決策權，並且Kymera將就[***]擁有最終決策權。

(e)

信息權利; [***].

(i)

針對[***]，每一方都將向JRDC提供由其或其關聯公司或轉讓方代表進行的或代表進行的活動摘要。此摘要將至少在[***]前提供給JRDC。

(ii)

對於[***]，各方應在最早的(a) [***]和(b) 各方達成相互一致（不得出於不合理原因而拒絕、附帶或延遲）之後[***]內向JRDC提交書面報告，總結活動的結果和交付成果，包括與這些活動相關生成的所有原始數據（「[***]」）。在一方請求時，JRDC將召開一個專門會議，審查和討論[***]，時間應在[***]內（「[***]」）；否則，審查和討論將在下次預定的JRDC會議上進行。

(f)

分包賽諾菲安萬特可能會與第三方承包商進行】下述活動；前提是(a)賽諾菲與第三方承包商之間的每份合同將包括保密和非使用條款，這些條款與第16條所規定的條款（或協定的其他條款）大體相同（但在爲類似目的簽訂的保密協議中慣常的期限內，對於構成商業祕密的任何信息，保密期將持續到該信息根據適用法律仍然屬於商業祕密爲止），(b)賽諾菲將始終對此協議下第三方承包商的行爲和疏忽承擔完全責任，如同這些行爲和疏忽是賽諾菲的行爲或疏忽，(c)賽諾菲將負責有效和及時管理和支付此處批准的第三方承包商，並且(d)賽諾菲與第三方承包商之間的每份合同將規定【***】。

1.3

Joint Research and Development Committee.

1.3.1

Sections 9.2.2(a) and 9.2.2(b) of the Agreement are hereby amended and restated in their entirety as follows:

9.2.2

Specific Responsibilities. The JRDC will, subject to the escalation, final decision-making authority and dispute resolution procedures in Section 9.9:

(a)

be responsible for overseeing the Parties’ performance of their respective activities under the Research Plan, Early Development Plan and [***] and provide support to each Party with respect to such Party’s activities thereunder;

(b)

review and discuss (i) each amended Research Plan, Early Development Plan and [***] and approve updates or material amendments to the Research Plan, Early Development Plan and [***] and (ii) the Phase 2 Development Plan and approve updates or material amendments to the Phase 2 Development Plan;

1.3.2

The following subsection (mm) is hereby added to Section 9.2.2 as follows:

(mm) review and discuss summaries, reports and data provided by the Parties pursuant to Section 2.4.8(e) in accordance with the terms thereof;

1.4

License Grant to Sanofi. Section 10.1.2 of the Agreement is hereby amended and restated in its entirety as follows:

10.1.2 Subject to the terms of this Agreement, on a Collaboration Target-by-Collaboration Target basis, during the Research Term, solely to the extent that Sanofi has any Step-In Activities, CMC activities, Manufacturing activities, or other activities under the Research Plan, Early Development Plan, [***] and Phase 2 Activities, as applicable, Kymera hereby grants to Sanofi a non-exclusive, non-royalty bearing license, including the right to grant Sublicenses in accordance with Section 10.3, under the Licensed Technology to perform such Step-In Activities, CMC activities, Manufacturing activities, or other activities under the Research Plan, Early Development Plan, [***] or Phase 2 Activities, as applicable.

1.5

License Grant to Kymera. Section 10.2 of the Agreement is hereby amended and restated in its entirety as follows:

10.2 License Grant to Kymera. Subject to the terms and conditions of this Agreement, including Section 8.1, on a Collaboration Target-by-Collaboration Target basis during the Term, Sanofi hereby grants to Kymera a non-exclusive license under (i) the Sanofi Technology, and (ii) the Exclusive Licenses under Section 10.1.3, each including the right to grant Sublicenses in accordance with Section 10.3, solely to perform Kymera’s obligations under this Agreement. The foregoing license to Kymera and its Affiliates includes, on a Collaboration Target-by-Collaboration Target basis, a license to Kymera and its Affiliates to (a) perform activities under the Research Plan, Early Development Plan and Backup Research Plan for a given Collaboration Target, (b) perform activities under the [***], (c) if Kymera exercises the Kymera Co-Promote Right for a Collaboration Target, to perform Co-Promotion activities for Opt-In Products Directed Against such Collaboration Target in the applicable Field in the United States, and (d) perform Manufacturing activities for Collaboration Compounds, Collaboration Candidates and Licensed Products Directed Against such Collaboration Target as set forth in this Agreement.

1.6

Ownership of [***] Technology. Section 12.1.2(b) of the Agreement is hereby amended and restated in its entirety as follows:

(b)

(i)

As between the Parties, Kymera will be the sole owner of any Foreground Know-How that [***], and will own and retain all rights, title and interest thereto, subject to any rights or licenses expressly granted by Kymera to Sanofi under this Agreement. For clarity, [***]. Any dispute of whether any [***] will be governed by Sections 9.9.2(b)(iii) and 9.9.2(b)(iv).

(ii)

As between the Parties, Kymera will be the sole owner of all Foreground Know-How [***]. For clarity, [***].

Except as specifically set forth in this Letter, the Agreement will continue in full force and effect without change. This Letter (together with all schedules and exhibits attached hereto) constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof. No amendment, modification or supplement of any provision of this Letter will be valid or effective unless made in writing and signed by a duly authorized officer of each of Sanofi and Kymera. No provision of this Letter will be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision

and signed by a duly authorized officer of the waiving Party. The waiver by either Party of any breach of any provision hereof by the other Party will not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself.

This Letter, and all claims arising under or in connection therewith, will be governed by and interpreted in accordance with the substantive laws of the State of New York, without regard to conflict of law principles thereof.

Yours Sincerely,

On behalf of Genzyme Corporation

By: /s/ John Bertin

Name: John Bertin

Title: Head of Immunology Research

Acknowledged and Agreed:

On behalf of Kymera Therapeutics, Inc.

By: /s/Nello Mainolfi

Name: Nello Mainolfi

Title: CEO